Nano Dimension Ltd is trading 14.4% down at $1.27 after announcing a proposed merger with AI health company Infinite Epigenetics, signaling a major strategic pivot away from industrial 3D printing.
- The non-binding term sheet envisions a transition into preventive health and diagnostics, with the combined entity rebranded under the Infinite Epigenetics name.
- Nano Dimension shareholders would retain only a minority stake in the new company, sparking investor concerns over valuation, corporate control, and the radical shift in business focus.